Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Avocados, fatty fish, salad dressing, nuts and yogurt are high-fat foods that can support weight loss. Fat provides energy ...

Obesity worsens asthma severity and responses to medication, yet most doctors fail to address weight management with these ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

Weight loss medication, such as GLP-1s and oral medications, can be useful for some to suppress your appetite and curb ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...